Opinion|Videos|July 29, 2024
Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant
A panel of experts discuss navigating 2L treatment strategies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are your perceptions on efficacy and safety data on PROTAC
ASCO 2024 #TPS1131 TACTIVE-K: Phase 1b/2 study of vepdegestrant plus CDK4i PF-07220060
- What are your perceptions on efficacy and safety data on SERM:
- Lasoxifene:
ASCO 2024 #TPS1127 : Phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib
- Lasoxifene:
- How do these options compare? Why might you choose one of these options vs fulvestrant?
Advertisement
Related to this article
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Breast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.
A new clinical trial will investigate whether a simple blood test could help detect breast cancer as early as Stage I.
Phase 3 data showed a significant PFS improvement with trastuzumab pamirtecan vs chemotherapy in HR-positive, HER2-low metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5